Takeda Tyks the deal-making box
For $4bn up front, Takeda buys into the Tyk2 mechanism – and Nimbus and its backers get a huge pay day.
Abeona takes on Amryt – and more importantly, Krystal
Three new epidermolysis bullosa therapies are approaching the US, and expectations vary wildly.
The other shoe drops for Immunic
Failure of a vital catalyst in psoriasis leaves Immunic’s approach at risk of obsolescence.
Go or no go? Bristol’s Tyk2 test
A green light from the FDA is expected for deucravacitinib, while Amylyx, Ferring and Oncopeptides head for panels.
Kymera’s pain could be Priovant’s gain
Pfizer’s Irak-4 inhibitor PF-06650833 definitely, definitely doesn’t work in hidradenitis suppurativa, but there’s at least partly better news for Priovant.
